Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 10, 2025, titled "Zydus launches biosimilar Denosumab 120 mg SC protecting bone health in cancer patients".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has announced the launch of a biosimilar version of Denosumab 120 mg in subcutaneous form. Denosumab is used to protect bone health in cancer patients, typically those with bone metastases from solid tumors, by preventing skeletal-related events. As a biosimilar, this product is a more affordable alternative to the original biologic already in the market. The launch expands Zydus's biosimilars portfolio and strengthens its presence in the oncology supportive care segment in India.
This is a positive commercial development — it adds a new revenue stream in a niche but growing oncology supportive care space and reinforces Zydus's biosimilar pipeline strategy. Near-term stock impact is likely to be modest, but it strengthens the company's long-term growth narrative in biosimilars.